ALTTO | ESMO Open

ALTTO | ESMO Open

OVERVIEW Dual anti-human epidermal growth factor receptor 2 (HER2) blockade has improved the outcomes of patients with early and metastatic HER2-positive breast cancer. The final 10-year analysis of the ALTTO trial is presented here. study details The Adjuvant...